رجوع
نطاق اليوم
KWD 2.24
KWD 2.37
نطاق 52 أسبوعًا
KWD 2.24
KWD 6.51
حجم التداول
5,894,713
متوسط 50 يوم / 200 يوم
KWD 4.66
/
KWD 4.80
الإغلاق السابق
KWD 2.28
Quick Summary
تاريخ السعر
الاتجاهات المالية
مقارنة الأقران
مقابل وسيط قطاع Healthcare (633 نظير)
| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | 120.9 | 0.2 |
| P/B | — | 3.0 |
| ROE % | — | 3.5 |
| Net Margin % | 1.7 | 3.8 |
| Rev Growth 5Y % | 46.7 | 9.7 |
| D/E | — | 0.2 |
السعر المستهدف للمحللين
Hold
KWD 9.00
+291.3%
ربحية السهم المستقبلية
-KWD 0.01
الإيرادات المقدّرة
467.59M
تقديرات الأرباح
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| FY2030 |
KWD 0.42
KWD 0.33 – KWD 0.46
|
730.26M | 5 |
| FY2029 |
KWD 0.20
KWD 0.16 – KWD 0.22
|
597.24M | 2 |
| FY2028 |
KWD 0.10
-KWD 0.12 – KWD 0.24
|
530.84M | 7 |
No quarterly estimates available
Earnings Surprises
Last 8 quarters
| Quarter | Est. EPS | Actual EPS | Surprise |
|---|---|---|---|
| 2026-02-26 | -KWD 0.01 | -KWD 0.05 | -400.0% |
| 2025-11-05 | KWD 0.01 | KWD 0.03 | +200.0% |
| 2025-08-06 | KWD 0.04 | KWD 0.00 | -94.7% |
| 2025-05-08 | KWD 0.03 | KWD 0.04 | +33.3% |
| 2025-02-26 | KWD 0.03 | KWD 0.03 | 0.0% |
| 2024-11-07 | KWD 0.06 | KWD 0.04 | -33.3% |
| 2024-08-07 | -KWD 0.03 | KWD 0.05 | +249.9% |
| 2024-05-08 | KWD 0.03 | KWD 0.04 | +53.8% |
Insider Trading Activity
20 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 1, 2026 |
HOOPER ANTHONY C
|
grant | 35,000 | KWD 3.27 | KWD 114,450.00 |
| Nov 11, 2025 |
Ahuja Ajay
Chief Medical Officer
|
grant | 318,200 | — | — |
| Jun 23, 2025 |
Marasco Dominic
Pres, Endocrine Business Unit
|
grant | 1,000,000 | — | — |
| May 19, 2025 |
Castagna Michael
Chief Executive Officer
|
other | 26,114 | KWD 4.37 | KWD 114,118.18 |
| May 14, 2025 |
Marasco Dominic
Pres, Endocrine Business Unit
|
grant | 153,929 | — | — |
| May 14, 2025 |
CONSIGLIO RONALD J
|
grant | 52,854 | — | — |
| May 14, 2025 |
Friedman Michael A
|
grant | 52,854 | — | — |
| May 14, 2025 |
MUNDKUR CHRISTINE
|
grant | 52,854 | — | — |
| May 14, 2025 |
Kay Sabrina
|
grant | 63,425 | — | — |
| May 14, 2025 |
Shannon James Samuel
|
grant | 52,854 | — | — |
| May 14, 2025 |
Grancio Jennifer
|
grant | 52,854 | — | — |
| May 14, 2025 |
HOOPER ANTHONY C
|
grant | 88,425 | KWD 4.56 | — |
| May 14, 2025 |
Binder Steven B.
|
grant | 52,854 | — | — |
| May 13, 2025 |
Prentiss Christopher B
Chief Financial Officer
|
grant | 264,000 | — | — |
| May 13, 2025 |
Singh Sanjay R
EVP Technical Operations
|
grant | 264,000 | — | — |
| May 13, 2025 |
Castagna Michael
Chief Executive Officer
|
grant | 951,000 | — | — |
| May 13, 2025 |
Tross Stuart A
Chief People & Workpl Officer
|
grant | 264,000 | — | — |
| May 13, 2025 |
Thomson David
EVP Genl Counsel & Secretary
|
sell | 32,179 | KWD 4.68 | KWD 150,597.72 |
| May 13, 2025 |
Thomson David
EVP Genl Counsel & Secretary
|
grant | 264,000 | — | — |
| May 13, 2025 |
Binder Steven B.
|
sell | 80,144 | KWD 4.69 | KWD 375,875.36 |
Dividend History
Yield
0.00%
Payout Ratio
0.00%
Growth (3Y)
N/A
Growth (5Y)
N/A
No dividend history available.
النقاط الرئيسية
Revenue grew 46.65% annually over 5 years — strong growth
Earnings declined -78.75% over the past year
Generating 13.69M in free cash flow
P/E of 120.86 — premium valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 24.42%
Cash machine — converts 233.48% of earnings into free cash flow
النمو
Revenue Growth (5Y)
46.65%
Revenue (1Y)22.23%
Earnings (1Y)-78.75%
FCF Growth (3Y)N/A
الجودة
Return on Equity
N/A
ROIC6.89%
Net Margin1.68%
Op. Margin11.12%
الأمان
Debt / Equity
N/A
Current Ratio1.70
Interest Coverage2.81
التقييم
P/E Ratio
120.86
Forward P/EN/A
P/B RatioN/A
EV/EBITDA28.53
Dividend Yield0.00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 22.23% | Revenue Growth (3Y) | 32.44% |
| Earnings Growth (1Y) | -78.75% | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 46.65% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 348.97M | Net Income (TTM) | 5.86M |
| ROE | N/A | ROA | 0.74% |
| Gross Margin | 82.47% | Operating Margin | 11.12% |
| Net Margin | 1.68% | Free Cash Flow (TTM) | 13.69M |
| ROIC | 6.89% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 1.70 |
| Interest Coverage | 2.81 | ||
| Dividends | |||
| Dividend Yield | 0.00% | Payout Ratio | 0.00% |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | 120.86 | Forward P/E | N/A |
| P/B Ratio | N/A | P/S Ratio | 2.03 |
| PEG Ratio | -3.69 | Forward PEG | N/A |
| EV/EBITDA | 28.53 | Fwd EV/EBITDA | N/A |
| Forward P/S | 1.52 | Fwd Earnings Yield | N/A |
| FCF Yield | 1.93% | ||
| Market Cap | 708.63M | Enterprise Value | 1.11B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 348.97M | 285.50M | 198.96M | 99.77M | 75.44M |
| Net Income | 5.86M | 27.59M | -11.94M | -87.40M | -80.93M |
| EPS (Diluted) | 0.02 | 0.10 | -0.04 | -0.44 | -0.37 |
| Gross Profit | 287.81M | 208.90M | 136.19M | 42.27M | 36.59M |
| Operating Income | 38.80M | 72.59M | 8.68M | -64.11M | -47.02M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 792.18M | 393.84M | 475.20M | 295.28M | 321.16M |
| Total Liabilities | 843.20M | 472.66M | 721.37M | 545.82M | 530.51M |
| Shareholders' Equity | -51.02M | -78.82M | -246.17M | -250.54M | -209.35M |
| Total Debt | 473.38M | 47.70M | 272.62M | 288.40M | 289.22M |
| Cash & Equivalents | 74.88M | 46.34M | 238.48M | 69.77M | 124.18M |
| Current Assets | 291.58M | 268.31M | 373.39M | 234.90M | 219.49M |
| Current Liabilities | 171.03M | 81.84M | 104.13M | 67.30M | 48.35M |